All Stories

  1. There are 100 ways by which the sympathetic nervous system can trigger life-threatening arrhythmias
  2. When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?
  3. From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2
  4. OUP accepted manuscript
  5. Modifier genes for sudden cardiac death
  6. Evolving concepts for the Long QT Syndrome
  7. Vox clamantis in deserto. We spoke but nobody was listening: echocardiography can help risk stratification of the long-QT syndrome
  8. Risk stratification for sudden cardiac death: current status and challenges for the future
  9. Drug-Induced Long QT Syndrome and Exome Sequencing
  10. Cardiac sympathetic denervation to prevent life-threatening arrhythmias
  11. Reply to the Editor— Propranolol Prevents Life-Threatening Arrhythmias in LQT3 Transgenic Mice: Implications for the Clinical Management of LQT3 Patients
  12. Sudden Death by Stress
  13. Left Cardiac Sympathetic Denervation in Patients with Heart Failure: a New Indication for an Old Intervention?
  14. Long and Short QT Syndromes
  15. Propranolol prevents life-threatening arrhythmias in LQT3 transgenic mice: Implications for the clinical management of LQT3 patients
  16. Refined multiscale entropy analysis of heart period and QT interval variabilities in long QT syndrome type-1 patients
  17. Congenital Long QT Syndrome
  18. Cardiac Channelopathies and Sudden Infant Death Syndrome
  19. PREDESTINATION: PRimary vEntricular fibrillation and suDden dEath during a firST myocardIal iNfArcTION: Genetic Basis
  20. When genetic screening for your patient with long QT syndrome comes back negative, don’t always take a no for a no
  21. Autonomic modulation for chronic heart failure: a new kid on the block?
  22. The Unstoppable Attraction for Induced Pluripotent Stem Cells
  23. Nadolol Block of Nav1.5 Does Not Explain Its Efficacy in the Long QT Syndrome
  24. Genetic Diseases
  25. Long QT syndrome: from genetic basis to treatment
  26. Sudden infant death syndrome and cardiac channelopathies: from mechanisms to prevention of avoidable tragedies
  27. Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion
  28. Pharmacological and non-pharmacological management of the congenital long QT syndrome: The rationale
  29. Sudden cardiac death, founder populations, and mushrooms: What is the link with gold mines and modifier genes?
  30. Inherited Cardiac Arrhythmia Syndrome: Role of Potassium Channels
  31. Neonatal Electrocardiogram 2002
  32. SIDS: The Role of LQTS and Its Implications for Prevention of Avoidable Tragedies
  33. The Search for Modifiers Genes in Long QT Syndrome and Its Impact on Management
  34. Prevention of Sudden Death in Inherited Arrhythmic Disorders: The Case of the Long QT Syndrome
  35. Vagal Stimulation for Heart Diseases: From Animals to Men
  36. Vagal stimulation for heart failure
  37. The Myth of QT Shortening by Weight Loss and Physical Training in Obese Subjects With Coronary Heart Disease
  38. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions
  39. Efficacy of left cardiac sympathetic denervation has an unforeseen side effect: Medicolegal complications
  40. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: The surgical supraclavicular approach to cervicothoracic sympathectomy
  41. Sympathetic–parasympathetic interaction in health and disease: abnormalities and relevance in heart failure
  42. Repolarization Abnormalities in the Newborn
  43. Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey
  44. The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation
  45. Non‐Pharmacologic Manipulation of the Autonomic Nervous System in Human for the Prevention of Life‐Threatening Arrhythmias
  46. Foreword
  47. Acknowledgement
  48. Vagal stimulation for heart failure: Background and first in-man study
  49. Of founder populations, long QT syndrome, and destiny
  50. NOS1AP Is a Genetic Modifier of Congenital Long-QT Syndrome
  51. Cutting nerves and saving lives
  52. All LQT3 patients need an ICD: True or false?
  53. Chronic vagal stimulation in patients with congestive heart failure
  54. Congenital long QT syndrome
  55. Risk of death in the long QT syndrome when a sibling has died
  56. Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic Ventricular Tachycardia
  57. Ion channel diseases in children: manifestations and management
  58. Prediction of unexpected sudden death among healthy dogs by a novel marker of autonomic neural activity
  59. Baroreflex Sensitivity Predicts Long-Term Cardiovascular Mortality After Myocardial Infarction Even in Patients With Preserved Left Ventricular Function
  60. Cardiac arrhythmias of genetic origin are important contributors to sudden infant death syndrome
  61. Can a Message From the Dead Save Lives?⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
  62. Newborn ECG screening to prevent sudden cardiac death
  63. Does Pregnancy Increase Cardiac Risk for LQT1 Patients With the KCNQ1-A341V Mutation?
  64. AB1-6
  65. P1-21
  66. AB1-5
  67. AB28-1
  68. The congenital long QT syndromes from genotype to phenotype: clinical implications
  69. Autonomic Nervous System: Emerging Concepts and Clinical Applications
  70. Management of long QT syndrome
  71. Heart-Rate Profile during Exercise as a Predictor of Sudden Death
  72. Phenotypic characterization of Timothy syndrome - a complex cardiac and multisystem disorder
  73. Cost concerns for implantable cardioverter defibrillators implant in post myocardial infarction patients: The value of autonomic markers
  74. How many cases of sudden infant death syndrome are due to the long QT syndrome?
  75. Common KCNH2 Polymorphism (K897T) as a genetic modifier of congenital long QT syndrome
  76. Long QT syndrome with cardiac arrest and transient short QT due to a novel KCNH2 mutation causing both loss and gain of function
  77. 1979-2004 : 25 YEARS OF THE INTERNATIONAL REGISTRY FOR THE LONG QT SYNDROME: ITS IMPACT ON KNOWLEDGE AND CLINICAL MANAGEMENT
  78. The Long QT Syndrome: A Clinical Counterpart of hERG Mutations
  79. CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism
  80. Long QT Syndrome: Genotype-Phenotype Correlations
  81. Prolonged Repolarization and Sudden Infant Death Syndrome
  82. How Really Rare Are Rare Diseases?:
  83. Hemodynamic Effects of a New Inotropic Compound, PST-2744, in Dogs With Chronic Ischemic Heart Failure
  84. Risk Stratification in the Long-QT Syndrome
  85. Combined Sodium and Calcium Channel Blockade in Prevention of Lethal Arrhythmias
  86. Counting Heart Beats:
  87. Report from the Task Force of the European Society of Cardiology for the interpretation of the neonatal electrocardiogram
  88. Continental Europe triumph in golf competition
  89. QT Prolongation, Sudden Death, and Sympathetic Imbalance: The Pendulum Swings
  90. Electrocardiography first for reducing cot death
  91. Another Role for the Sympathetic Nervous System in the Long QT Syndrome?
  92. QT or Not QT?
  93. Significance of QT dispersion in the long QT syndrome
  94. SEVERE CHRONIC STRESS OFTEN PRECEDES IDIOPATHIC VENTRICULAR FIBRILLATION (IVF)
  95. Two‐to‐One AV Block Associated with the Congenital Long QT Syndrome
  96. Mortality in the Survival With ORal D-Sotalol (SWORD) Trial: Why Did Patients Die? 11This work was supported by a grant from Bristol-Myers Squibb, Princeton, New Jersey.
  97. Do Animal Models Have Clinical Value?
  98. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
  99. The Long QT Syndrome
  100. Neuroanatomical correlates of pleasant and unpleasant emotion
  101. Baroreflex Sensitivity as a Cardiac and Arrhythmia Mortality Risk Stratifier
  102. Effects of β-adrenergic blockade on dispersion of ventricular repolarization in newborn infants with prolonged QT interval
  103. Molecular Biology of the Long QT Syndrome: Impact on Management
  104. The long QT syndrome
  105. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators
  106. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
  107. Mortality in the survival with ORal D-sotalol (SWORD) trial: Why did patients die?
  108. Principal component analysis of repolarization: A novel index of complexity of ventricular repolarization in the long QT syndrome
  109. The influence of beta-blockers on QT interval in patients with long QT syndrome
  110. Differential response to mexiletine, catecholamines and pacing, in a cellular model mimicking the SCN5A and HERG genes defect present in the long QT syndrome
  111. Effects of gender on the dynamic relation between ventricular repolarization and heart rate
  112. Dynamic relation between ventricular repolarization and heart rate in the long QT syndrome
  113. Use of baroreceptor reflex sensitivity in the prediction of risk after myocardial infarction
  114. Left Cardiac Sympathetic Denervation in Long QT Syndrome Patients
  115. Baroreflex Sensitivity
  116. Are gender differences in QTc present at birth?
  117. Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial)
  118. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia
  119. Malignant arrhythmias and acute myocardial ischemia: Interaction between flecainide and the autonomic nervous system
  120. Torsade de Pointes
  121. Alpha1‐Adrenergic Blockade and Sudden Cardiac Death
  122. Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death
  123. Prevention of life-threatening arrhythmias by pharmacologic stimulation of the muscarinic receptors with oxotremorine
  124. Pathophysiological mechanisms of sudden infant death syndrome
  125. Dispersion of ventricular repolarization in the long QT syndrome
  126. Effect of reflex vagal activation on frequency of ventricular premature complexes
  127. Cardiac Pain, Sympathetic Afferents, and Life‐Threatening Arrhythmias
  128. Electrophysiologic mechanisms involved in the development of torsades de pointes
  129. Sympathetic — Parasympathetic Interaction and Sudden Death
  130. Autonomic Nervous System and Arrhythmiasa
  131. Postnatal development of cardiac innervation and susceptibility to malignant arrhythmias in the dog
  132. The familial long QT syndrome study: Prospective cardiac and genetic investigation involving 292 families
  133. Carbon monoxide and lethal arrhythmias in conscious dogs with a healed myocardial infarction
  134. Cardiac Innervation and Sudden Death: New Strategies for Prevention
  135. Demonstration of a different sensitivity to epinephrine in isolated and in vivo hearts
  136. Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: Effect of nifedipine
  137. The Role of Left Stellectomy in the Prevention of Lethal Arrhythmias
  138. The Influence of the Autonomic Nervous System on Sudden Cardiac Death
  139. Mexiletine in the Prevention of Sudden Cardiac Death: Experimental Evaluation and Clinical Implications
  140. Lack of correlation between occlusion and reperfusion arrhythmias in the cat
  141. Idiopathic long QT syndrome: Progress and questions
  142. Role of the Autonomic Nervous System in the Genesis of Early Ischemic Arrhythmias
  143. THE RATIONALE AND THE ROLE OF LEFT STELLECTOMY FOR THE PREVENTION OF MALIGNANT ARRHYTHMIAS
  144. Neural Factors in Sudden Death
  145. T‐Wave Amplitude as an Index of Cardiac Sympathetic Activity: A Misleading Concept
  146. The Idiopathic Long Q-T Syndrome
  147. Left stellectomy and denervation supersensitivity in conscious dogs
  148. Cardiac Arrhythmias Elicited by Interaction Between Acute Myocardial Ischemia and Sympathetic Hyperactivity
  149. Neural mechanisms in life-threatening arrhythmias
  150. Sudden death and the idiopathic long Q-T syndrome
  151. Sudden infant death, long Q-T interval and long Q-T syndrome
  152. Effects of unilateral stellate ganglion blockade on the arrhythmias associated with coronary occlusion
  153. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold
  154. The long Q-T syndrome
  155. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold
  156. Reflex responses of sympathetic preganglionic neurones initiated by different cardiovascular receptors in spinal animals
  157. Reflex changes in cardiac vagal efferent nervous activity elicited by stimulation of afferent fibres in the cardiac sympathetic nerves
  158. A cardiac murmur depending on the Wolff-Parkinson-White syndrome
  159. Prolonged Repolarization and Sudden Infant Death Syndrome
  160. Sudden Cardiac Death in Infancy: Focus on Prolonged Repolarization
  161. Congenital Long QT Syndrome